Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class (Descending) Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
42388-0025-57 42388-0025 Cabozantinib CABOMETYX 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR Oral Jan. 9, 2023 In Use
50742-0366-30 50742-0366 Gefitinib Gefitinib 250.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral April 27, 2023 In Use
51407-0760-12 51407-0760 Sorafenib Sorafenib 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FLT, PDGFR, KIT, RET, RET/PTC, CRAF, BRAF Oral April 14, 2023 In Use
63539-0927-01 63539-0927 Lorlatinib Lorbrena 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ALK/ROS1 Oral Jan. 3, 2023 In Use
65597-0407-20 65597-0407 Pexidartinib hydrochloride Turalio 125.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor CSF1R, KIT, FLT3 Oral Feb. 1, 2023 In Use
65597-0407-28 65597-0407 Pexidartinib hydrochloride Turalio 125.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor CSF1R, KIT, FLT3 Oral Feb. 1, 2023 In Use
67184-0531-01 67184-0531 Gefitinib Gefitinib 250.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Feb. 13, 2023 In Use
67184-0531-02 67184-0531 Gefitinib Gefitinib 250.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Feb. 13, 2023 In Use
67184-0531-03 67184-0531 Gefitinib Gefitinib 250.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Feb. 13, 2023 In Use
00069-0135-01 00069-0135 Bosutinib monohydrate, Bosutinib Bosulif 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sept. 4, 2012 In Use
00069-0136-01 00069-0136 Bosutinib monohydrate, Bosutinib Bosulif 500.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sept. 4, 2012 In Use
00069-0193-01 00069-0193 Bosutinib monohydrate, Bosutinib BOSULIF 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Dec. 18, 2017 In Use
00480-4184-89 00480-4184 Pazopanib Pazopanib 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, PDGFR, FGFR, Kit, Itk, Lck, c-Fms Oral Oct. 20, 2023 In Use
00054-0248-12 00054-0248 Imatinib Mesylate Imatinib Mesylate 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sept. 28, 2018 In Use
00054-0248-22 00054-0248 Imatinib Mesylate Imatinib Mesylate 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sept. 28, 2018 In Use
00054-0249-12 00054-0249 Imatinib Mesylate Imatinib Mesylate 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sept. 28, 2018 In Use
00054-0249-13 00054-0249 Imatinib Mesylate Imatinib Mesylate 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sept. 28, 2018 In Use
00054-0249-22 00054-0249 Imatinib Mesylate Imatinib Mesylate 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sept. 28, 2018 In Use
00069-0251-60 00069-0251 CRIZOTINIB Xalkori 20.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ALK, HGFR, ROS1, RON Oral Nov. 20, 2023 In Use
00069-0507-60 00069-0507 CRIZOTINIB Xalkori 50.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ALK, HGFR, ROS1, RON Oral Nov. 20, 2023 In Use
00069-1500-60 00069-1500 CRIZOTINIB Xalkori 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ALK, HGFR, ROS1, RON Oral Nov. 20, 2023 In Use
51144-0002-12 51144-0002 Tucatinib TUKYSA 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor HER2 Oral April 17, 2020 In Use
51144-0002-60 51144-0002 Tucatinib TUKYSA 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor HER2 Oral April 17, 2020 In Use
50419-0392-01 50419-0392 LAROTRECTINIB VITRAKVI 20.0 mg/mL Chemotherapy Tyrosine Kinase Inhibitor TRK OROPHARYNGEAL July 26, 2019 In Use
51144-0001-60 51144-0001 Tucatinib TUKYSA 50.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor HER2 Oral April 17, 2020 In Use

Found 10,000 results in 3 milliseconds — Export these results